AIM:To elucidate the role of vascular endothelial growth factor-165b(VEGF-165b)in blood-retinal barrier(BRB)injury in the rat acute glaucoma model.METHODS:In this study,the rat acute high intraocular pressure(HIOP)mod...AIM:To elucidate the role of vascular endothelial growth factor-165b(VEGF-165b)in blood-retinal barrier(BRB)injury in the rat acute glaucoma model.METHODS:In this study,the rat acute high intraocular pressure(HIOP)model was established before and after intravitreous injection of anti-VEGF-165b antibody.The expression of VEGF-165b and zonula occludens-1(ZO-1)in rat retina was detected by double immunofluorescence staining and Western blotting,and the breakdown of BRB was detected by Evans blue(EB)dye.RESULTS:The intact retina of rats expressed VEGF-165b and ZO-1 protein,which were mainly located in the retinal ganglion cell layer and the inner nuclear layer and were both co-expressed with vascular endothelial cell markers CD31.After acute HIOP,the expression of VEGF-165b was up-regulated;the expression of ZO-1 was down-regulated at 12h and then recovered at 3d;EB leakage increased,peaking at 12h.After intravitreous injection of anti-VEGF-165b antibody,the expression of VEGF-165b protein was no significantly changed;and the down-regulation of the expression of ZO-1 was more obvious;EB leakage became more serious,peaking at 3d.EB analysis also showed that EB leakage in the peripheral retina was greater than that in the central retina.CONCLUSION:The endogenous VEGF-165b protein may protect the BRB from acute HIOP by regulating the expression of ZO-1.The differential destruction of BRB after acute HIOP may be related to the selective loss of retinal ganglion cells.展开更多
目的研究VEGF165b和VEGF165在胃癌及癌旁正常组织中的表达及胃癌组织中VEGF165b m RNA/VEGF165 m RNA与预后的关系。方法分别应用实时RT-PCR和免疫组织化学法检测胃癌及癌旁正常组织中VEGF165b和VEGF165的基因及蛋白表达,并对患者进行2...目的研究VEGF165b和VEGF165在胃癌及癌旁正常组织中的表达及胃癌组织中VEGF165b m RNA/VEGF165 m RNA与预后的关系。方法分别应用实时RT-PCR和免疫组织化学法检测胃癌及癌旁正常组织中VEGF165b和VEGF165的基因及蛋白表达,并对患者进行2年的随访,比较VEGF165b m RNA/VEGF165 m RNA比值及这两种蛋白表达水平在胃癌及癌旁组织中的变化;同时分析VEGF165b与VEGF165蛋白表达的相关性以及胃癌组织中VEGF165b m RNA/VEGF165 m RNA与预后的关系。结果在胃癌组织中VEGF165b m RNA/VEGF165 m RNA低于癌旁正常组织中的水平;在癌旁正常组织中VEGF165b基因及蛋白表达强于VEGF165,在胃癌组织中VEGF165b基因及蛋白的表达则低于VEGF165,而且两者表达呈负相关关系;此外,在两年内死亡的患者中VEGF165b m RNA/VEGF165 m RNA明显低于生存患者中的比值水平。结论与正常组织相比,胃癌组织中存在VEGF165b向VEGF165基因及蛋白水平上的优势转换,这种变化有望成为治疗胃癌的新靶点。展开更多
目的:对比观察VEGF165b重组蛋白(recombinant human VEGF165b protein,rhVEGF165b)与贝伐珠单抗对人胃癌裸鼠移植瘤生长的影响及作用机制.方法:用人胃癌细胞BGC-823接种于裸鼠皮下,建立裸鼠移植瘤模型,随机分为3组,每组21只:rhVEGF165b...目的:对比观察VEGF165b重组蛋白(recombinant human VEGF165b protein,rhVEGF165b)与贝伐珠单抗对人胃癌裸鼠移植瘤生长的影响及作用机制.方法:用人胃癌细胞BGC-823接种于裸鼠皮下,建立裸鼠移植瘤模型,随机分为3组,每组21只:rhVEGF165b组(腹腔注射rhVEGF165b 10?g/kg)、贝伐珠单抗组(腹腔注射贝伐珠单抗5 mg/kg)、对照组(腹腔注射生理盐水10 mL/kg),分别于1、2、3 wk测量裸鼠移植瘤体积及瘤质量,免疫组织化学方法检测肿瘤组织中CD34表达(以阳性细胞数计算肿瘤微血管密度),TUNEL方法检测肿瘤组织细胞凋亡.结果:贝伐珠单抗组移植瘤体积(cm3)及瘤质量(g)在第1、2、3周均小于对照组(1 wk:0.453±0.119 vs 0.637±0.084,0.32±0.097vs 0.46±0.093;2 wk:1.691±0.381 vs 2.238±0.29,1.168±0.524 vs 2.013±0.833;3 wk:1.709±0.474 vs 4.872±0.594,1.747±0.557 vs3.463±0.986,均P<0.05),而rhVEGF165b组仅在第1、2周较对照组小(1 wk:0.546±0.132 vs0.637±0.084,1.894±0.599 vs 0.46±0.093;2wk:1.894±0.599 vs 2.238±0.29,1.537±0.568vs 2.013±0.833,均P<0.05),第3周其体积及瘤质量大于贝伐珠单抗组(3 wk:3.843±1.339 vs1.709±0.474,3.066±1.281 vs 1.747±0.557,P<0.05),与对照组无明显差异.rhVEGF165b组、贝伐珠单抗组CD34的表达水平在第1、2、3周均低于对照组(P<0.05,P<0.01),凋亡指数高于对照组(P<0.05,P<0.01);与贝伐珠单抗组相比,第1周rhVEGF165b组CD34的表达水平更低(P<0.05),但第2、3周却高于贝伐珠单抗组(P<0.01);rhVEGF165b组的凋亡指数在第1周明显高于贝伐珠单抗组(P<0.01),而第2、3周却低于贝伐珠单抗组(P<0.05).结论:rhVEGF165b、贝伐珠单抗对人胃癌移植瘤的生长有明显抑制作用,rhVEGF165b早期抑制血管生成、促进细胞凋亡表现更为明显.展开更多
目的:初步探讨VEGF165b与膀胱移行细胞癌(Transitional cell carcinoma of the bladder,TCCB)发生发展的关系。方法:用S-P免疫组化法检测38例TCCB组织和36例正常膀胱组织中VEGF165b蛋白表达;以RT-PCR法检测55例TCCB组织和43例正常膀胱...目的:初步探讨VEGF165b与膀胱移行细胞癌(Transitional cell carcinoma of the bladder,TCCB)发生发展的关系。方法:用S-P免疫组化法检测38例TCCB组织和36例正常膀胱组织中VEGF165b蛋白表达;以RT-PCR法检测55例TCCB组织和43例正常膀胱组织中VEGF165bmRNA表达。结果:正常膀胱组织中VEGF165b蛋白表达率为97.22%(35/36),TCCB组织中VEGF165b蛋白表达率为21.05%(8/38),表达差异有显著性(P<0.05);正常膀胱组织中VEGF165bmRNA阳性表达率为95.35%(41/43),明显高于TCCB组织中VEGF165bmRNA阳性表达率18.18%(10/55)(P<0.05);TCCB中VEGF165b蛋白和mRNA的表达与TCCB不同分期、分级间的表达差异具有统计学意义(P<0.05)。结论:VEGF165b在TCCB组织中的表达明显低于正常膀胱组织中的表达,这种表达差异可能与VEGF165b抑制膀胱癌的发生、发展作用有关。展开更多
基金Supported by the National Natural Science Foundation of China(No.81660217)Youth Foundation of the First Affiliated Hospital of Hainan Medical University(No.HYYFYPY201922)。
文摘AIM:To elucidate the role of vascular endothelial growth factor-165b(VEGF-165b)in blood-retinal barrier(BRB)injury in the rat acute glaucoma model.METHODS:In this study,the rat acute high intraocular pressure(HIOP)model was established before and after intravitreous injection of anti-VEGF-165b antibody.The expression of VEGF-165b and zonula occludens-1(ZO-1)in rat retina was detected by double immunofluorescence staining and Western blotting,and the breakdown of BRB was detected by Evans blue(EB)dye.RESULTS:The intact retina of rats expressed VEGF-165b and ZO-1 protein,which were mainly located in the retinal ganglion cell layer and the inner nuclear layer and were both co-expressed with vascular endothelial cell markers CD31.After acute HIOP,the expression of VEGF-165b was up-regulated;the expression of ZO-1 was down-regulated at 12h and then recovered at 3d;EB leakage increased,peaking at 12h.After intravitreous injection of anti-VEGF-165b antibody,the expression of VEGF-165b protein was no significantly changed;and the down-regulation of the expression of ZO-1 was more obvious;EB leakage became more serious,peaking at 3d.EB analysis also showed that EB leakage in the peripheral retina was greater than that in the central retina.CONCLUSION:The endogenous VEGF-165b protein may protect the BRB from acute HIOP by regulating the expression of ZO-1.The differential destruction of BRB after acute HIOP may be related to the selective loss of retinal ganglion cells.
文摘目的研究VEGF165b和VEGF165在胃癌及癌旁正常组织中的表达及胃癌组织中VEGF165b m RNA/VEGF165 m RNA与预后的关系。方法分别应用实时RT-PCR和免疫组织化学法检测胃癌及癌旁正常组织中VEGF165b和VEGF165的基因及蛋白表达,并对患者进行2年的随访,比较VEGF165b m RNA/VEGF165 m RNA比值及这两种蛋白表达水平在胃癌及癌旁组织中的变化;同时分析VEGF165b与VEGF165蛋白表达的相关性以及胃癌组织中VEGF165b m RNA/VEGF165 m RNA与预后的关系。结果在胃癌组织中VEGF165b m RNA/VEGF165 m RNA低于癌旁正常组织中的水平;在癌旁正常组织中VEGF165b基因及蛋白表达强于VEGF165,在胃癌组织中VEGF165b基因及蛋白的表达则低于VEGF165,而且两者表达呈负相关关系;此外,在两年内死亡的患者中VEGF165b m RNA/VEGF165 m RNA明显低于生存患者中的比值水平。结论与正常组织相比,胃癌组织中存在VEGF165b向VEGF165基因及蛋白水平上的优势转换,这种变化有望成为治疗胃癌的新靶点。
文摘目的:对比观察VEGF165b重组蛋白(recombinant human VEGF165b protein,rhVEGF165b)与贝伐珠单抗对人胃癌裸鼠移植瘤生长的影响及作用机制.方法:用人胃癌细胞BGC-823接种于裸鼠皮下,建立裸鼠移植瘤模型,随机分为3组,每组21只:rhVEGF165b组(腹腔注射rhVEGF165b 10?g/kg)、贝伐珠单抗组(腹腔注射贝伐珠单抗5 mg/kg)、对照组(腹腔注射生理盐水10 mL/kg),分别于1、2、3 wk测量裸鼠移植瘤体积及瘤质量,免疫组织化学方法检测肿瘤组织中CD34表达(以阳性细胞数计算肿瘤微血管密度),TUNEL方法检测肿瘤组织细胞凋亡.结果:贝伐珠单抗组移植瘤体积(cm3)及瘤质量(g)在第1、2、3周均小于对照组(1 wk:0.453±0.119 vs 0.637±0.084,0.32±0.097vs 0.46±0.093;2 wk:1.691±0.381 vs 2.238±0.29,1.168±0.524 vs 2.013±0.833;3 wk:1.709±0.474 vs 4.872±0.594,1.747±0.557 vs3.463±0.986,均P<0.05),而rhVEGF165b组仅在第1、2周较对照组小(1 wk:0.546±0.132 vs0.637±0.084,1.894±0.599 vs 0.46±0.093;2wk:1.894±0.599 vs 2.238±0.29,1.537±0.568vs 2.013±0.833,均P<0.05),第3周其体积及瘤质量大于贝伐珠单抗组(3 wk:3.843±1.339 vs1.709±0.474,3.066±1.281 vs 1.747±0.557,P<0.05),与对照组无明显差异.rhVEGF165b组、贝伐珠单抗组CD34的表达水平在第1、2、3周均低于对照组(P<0.05,P<0.01),凋亡指数高于对照组(P<0.05,P<0.01);与贝伐珠单抗组相比,第1周rhVEGF165b组CD34的表达水平更低(P<0.05),但第2、3周却高于贝伐珠单抗组(P<0.01);rhVEGF165b组的凋亡指数在第1周明显高于贝伐珠单抗组(P<0.01),而第2、3周却低于贝伐珠单抗组(P<0.05).结论:rhVEGF165b、贝伐珠单抗对人胃癌移植瘤的生长有明显抑制作用,rhVEGF165b早期抑制血管生成、促进细胞凋亡表现更为明显.
文摘目的:初步探讨VEGF165b与膀胱移行细胞癌(Transitional cell carcinoma of the bladder,TCCB)发生发展的关系。方法:用S-P免疫组化法检测38例TCCB组织和36例正常膀胱组织中VEGF165b蛋白表达;以RT-PCR法检测55例TCCB组织和43例正常膀胱组织中VEGF165bmRNA表达。结果:正常膀胱组织中VEGF165b蛋白表达率为97.22%(35/36),TCCB组织中VEGF165b蛋白表达率为21.05%(8/38),表达差异有显著性(P<0.05);正常膀胱组织中VEGF165bmRNA阳性表达率为95.35%(41/43),明显高于TCCB组织中VEGF165bmRNA阳性表达率18.18%(10/55)(P<0.05);TCCB中VEGF165b蛋白和mRNA的表达与TCCB不同分期、分级间的表达差异具有统计学意义(P<0.05)。结论:VEGF165b在TCCB组织中的表达明显低于正常膀胱组织中的表达,这种表达差异可能与VEGF165b抑制膀胱癌的发生、发展作用有关。
